Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine Department of Surgery
mi
from
Saint Louis, MO
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine Department of Surgery
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated:  12/31/1969
Aurora Health Care
mi
from
West Allis, WI
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated: 12/31/1969
Aurora Health Care
mi
from
West Allis, WI
Click here to add this to my saved trials
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated:  12/31/1969
Sutter Institute for Medical Research
mi
from
Vacaville, CA
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated: 12/31/1969
Sutter Institute for Medical Research
mi
from
Vacaville, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated:  12/31/1969
Beaumont Health System
mi
from
Royal Oak, MI
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated: 12/31/1969
Beaumont Health System
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated:  12/31/1969
MetroHealth System, Center for Advanced Gynecology
mi
from
Cleveland, OH
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated: 12/31/1969
MetroHealth System, Center for Advanced Gynecology
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated:  12/31/1969
Philadelphia Urosurgical Associates
mi
from
Philadelphia, PA
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions
A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Status: Enrolling
Updated: 12/31/1969
Philadelphia Urosurgical Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated:  12/31/1969
Univeristy of California at Los Angeles
mi
from
Los Angeles, CA
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated: 12/31/1969
Univeristy of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated:  12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated: 12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated:  12/31/1969
Gastrointestinal Associates
mi
from
Knoxville, TN
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated: 12/31/1969
Gastrointestinal Associates
mi
from
Knoxville, TN
Click here to add this to my saved trials
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
Cytosponge Adequacy Study Evaluation II
Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
TECR & ECM Placement for Esophageal High Grade Dysplasia
A Prospective Feasibility Study to Evaluate the Safety and Efficacy of Transoral Endoscopic Circumferential Esophageal Resection With Extracellular Matrix (ECM) Placement to Treat Barrett's Esophagus With High-grade Dysplasia (HGD)
Status: Enrolling
Updated:  12/31/1969
West Penn Allegheny Health System
mi
from
Pittsburgh, PA
TECR & ECM Placement for Esophageal High Grade Dysplasia
A Prospective Feasibility Study to Evaluate the Safety and Efficacy of Transoral Endoscopic Circumferential Esophageal Resection With Extracellular Matrix (ECM) Placement to Treat Barrett's Esophagus With High-grade Dysplasia (HGD)
Status: Enrolling
Updated: 12/31/1969
West Penn Allegheny Health System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
A Multidisciplinary Approach to Deciphering the Mechanisms Involved In Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
A Multidisciplinary Approach to Deciphering the Mechanisms Involved In Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Scottsdale, AZ
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
South Denver Gastroenterology
mi
from
Lone Tree, CO
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
South Denver Gastroenterology
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Group of Naples
mi
from
Naples, FL
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Group of Naples
mi
from
Naples, FL
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Associates of Central Georgia
mi
from
Macon, GA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Associates of Central Georgia
mi
from
Macon, GA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Medical Diagnostic Center (MDC)-Indiana University (IU) Health University Hospital
mi
from
Indianapolis, IN
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Medical Diagnostic Center (MDC)-Indiana University (IU) Health University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Iowa Digestive Disease Center
mi
from
Clive, IA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Iowa Digestive Disease Center
mi
from
Clive, IA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Cotton-O'Neil Clinical Research Center, Digestive Health
mi
from
Topeka, KA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Cotton-O'Neil Clinical Research Center, Digestive Health
mi
from
Topeka, KA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Delta Research Partners, LLC
mi
from
Monroe, LA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Delta Research Partners, LLC
mi
from
Monroe, LA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Institute of Michigan,
mi
from
Chesterfield, MI
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Institute of Michigan,
mi
from
Chesterfield, MI
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center & New York Presbyterian
mi
from
New York, NY
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center & New York Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, NY
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Great Lakes Gastroenterology
mi
from
Mentor, OH
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Great Lakes Gastroenterology
mi
from
Mentor, OH
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Gastro One
mi
from
Germantown, TN
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Gastro One
mi
from
Germantown, TN
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Texas Clinical Research Institute
mi
from
Arlington, TX
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Texas Clinical Research Institute
mi
from
Arlington, TX
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Ertan Digestive Disease Center of Excellence, UTH/MH-TMC
mi
from
Houston, TX
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Ertan Digestive Disease Center of Excellence, UTH/MH-TMC
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Research Of San Antonio
mi
from
San Antonio, TX
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Research Of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Digestive and Liver Disease Specialists
mi
from
Norfolk, VA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Digestive and Liver Disease Specialists
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Mcguire Dvamc
mi
from
Richmond, VA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Mcguire Dvamc
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Concord Repatriation General Hospital
mi
from
Concord,
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Concord Repatriation General Hospital
mi
from
Concord,
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
AGA Clinical Research Associates, LLC
mi
from
Egg Harbor Township, NJ
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
AGA Clinical Research Associates, LLC
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
Status: Enrolling
Updated:  12/31/1969
University of South Alabama /ID# 137255
mi
from
Mobile, AL
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
Status: Enrolling
Updated: 12/31/1969
University of South Alabama /ID# 137255
mi
from
Mobile, AL
Click here to add this to my saved trials
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
Status: Enrolling
Updated:  12/31/1969
Phoenix Childrens Hospital /ID# 141336
mi
from
Phoenix, AZ
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
Status: Enrolling
Updated: 12/31/1969
Phoenix Childrens Hospital /ID# 141336
mi
from
Phoenix, AZ
Click here to add this to my saved trials